AssetMark Inc’s Viking Therapeutics VKTX Stock Holding History

AssetMark Inc’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$142K	Sell	3,634 -236	-6%	-$7.62K	﹤0.01%	1540
2026 Q1	$126K	Buy	3,870 +462	+14%	+$14.8K	﹤0.01%	1467
2025 Q4	$120K	Sell	3,408 -8,989	-73%	-$319K	﹤0.01%	1436
2025 Q3	$326K	Sell	12,397 -520	-4%	-$15.5K	﹤0.01%	1165
2025 Q2	$342K	Buy	12,917 +2	+0%	+$53	﹤0.01%	1109
2025 Q1	$312K	Buy	12,915 +789	+7%	+$24.9K	﹤0.01%	1063
2024 Q4	$488K	Buy	12,126 +1,637	+16%	+$93.3K	﹤0.01%	961
2024 Q3	$664K	Buy	10,489 +9,198	+712%	+$540K	﹤0.01%	851
2024 Q2	$68.4K	Buy	1,291 +528	+69%	+$34.6K	﹤0.01%	1174
2024 Q1	$62.6K	Buy	+763	New	+$34K	﹤0.01%	1123

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

AssetMark Inc's VKTX Position: Q2 2026 in Review

AssetMark Inc reduced its Viking Therapeutics (VKTX) stake by 6.1% in Q2 2026, selling an estimated $7.62K and leaving 3,634 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

AssetMark Inc first reported a position in VKTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $664K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

AssetMark Inc held 3,634 shares of Viking Therapeutics worth $142K as of Q2 2026.
AssetMark Inc sold 236 Viking Therapeutics shares in Q2 2026, an estimated $7.62K.
Viking Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1540 holding.
AssetMark Inc first reported a position in Viking Therapeutics in Q1 2024 and has held it in 10 quarters since.
AssetMark Inc's Viking Therapeutics position peaked at $664K in Q3 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.